New Research Presented at CHEST 2013 Conference Highlights Breathe Technologies' Non-invasive Open Ventilation System
Presentations Follow Recent Clinical Study in American Journal of Respiratory Critical Care Medicine (AJRCCM) Demonstrating Dramatic Improvements in Shortness of Breath and Exercise Endurance for COPD Patients; The AJRCCM Study Shows NIOV System Provides Significant Improvement Over Standard of Care
(firmenpresse) - IRVINE, CA -- (Marketwired) -- 10/23/13 -- , the developer and manufacturer of innovative medical technologies to treat lung diseases, announced that two presentations at the CHEST 2013 meeting in Chicago, October 26-31 will highlight research conducted using the company's . These presentations come on the heels of a recent publication in the , which demonstrated the NIOV System's effectiveness in providing dramatic improvements in shortness of breath and exercise endurance for patients with Chronic Obstructive Pulmonary Disease (COPD). The NIOV System is a 1-lb, wearable, ambulatory ventilation system for the treatment of symptoms associated with variety of respiratory insufficiency diseases.
The two presentations at CHEST highlighting the NIOV System are as follows:
An oral presentation, "Effect of the Breathe Noninvasive Open Ventilation (NIOV) Device on Breathing Pattern of Patients with Severe COPD" will be delivered by Matthew Cohn, M.D., Clinical Associate, Tufts University School of Medicine, during the Dyspnea in session, on Sunday October 27, 2013. This presentation highlights research conducted in conjunction with Nicholas Hill, M.D., Professor of Medicine; Chief, Pulmonary, Critical Care, and Sleep Division, Department of Medicine, Tufts University School of Medicine.
A poster presentation titled "Effects of Noninvasive Open Ventilator on the Tidal Volume and Inspiratory Effort During Exercise in Severe COPD" will be delivered by Robert Cao, M.D., Research Associate, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, during the COPD Treatment Poster session, on Wednesday, October 30, 2013.
Dr. Cao's presentation will be a new data analysis based upon his recently co-authored study "Physiologic Effects of an Ambulatory Ventilation System in Chronic Obstructive Pulmonary Disease" published in AJRCCM. Dr. Cao co-authored the study with Richard Casaburi, M.D. M. Eng., Ph.D. Professor of Medicine, Associate Chief of Research, Division of Respiratory and Critical Care Physiology, UCLA David Geffen School of Medicine and Janos Porszasz, M.D., Ph.D., Adjunct Professor of Medicine, Technical Director, Rehabilitation Clinical Trials Center, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center. The study demonstrated the effectiveness of the NIOV System in the treating the symptoms associated with advanced stage COPD, including shortness of breath and exercise endurance. The AJRCCM study compared the NIOV System to the current standard of care, long term oxygen therapy (LTOT), and demonstrated the following:
54% increase in exercise endurance
28% reduction in Borg Dyspnea Scale, a measurement of shortness of breath
46% reduction in accessory respiratory muscle activation
Increased and maintained oxygen saturation levels during exercise from 92.7% to 98.5%
"Our study indicates that the NIOV System dramatically prolongs exercise tolerance. The magnitude of this improvement is substantially greater than what we have observed with either bronchodilator or routine oxygen therapy. It is similar to the improvements seen with pulmonary rehabilitation," said Dr. Casaburi.
Patients living with COPD may be limited in their ability to participate in activities of daily living and exercise due to the symptoms associated with their disease. The NIOV System was designed to address these symptoms and facilitate ambulation. Research, such as the recent study in the AJRCCM, demonstrates the clinical efficacy of the NIOV System in reducing dyspnea, unloading respiratory muscles and improving exercise endurance.
"We believe the NIOV System may become a new standard of care for the treatment of patients with respiratory insufficiency," said Larry Mastrovich, president and CEO of Breathe Technologies, Inc. "NIOV has the potential to transform COPD patients' quality of life by reducing shortness of breath and increasing exercise endurance, allowing them to lead more active and independent lives."
The NIOV System is a 1-lb, wearable, ambulatory ventilation system for the treatment of symptoms associated with a variety of respiratory insufficiency diseases. The NIOV System increases tidal volume by providing positive pressure ventilation that has been shown(1) to significantly:
Improve ventilation
Reduce dyspnea
Increase oxygenation
Significantly enhance exercise endurance
Unload respiratory muscle activity
The NIOV System is designed for applications such as supporting activities of daily living, patient ambulation, physical therapy, and pulmonary rehabilitation in either home or institutional environments.
is a developer and manufacturer of innovative medical technologies that have the potential to dramatically improve quality of life in the treatment of lung diseases. The company's first product, the , is cleared by the FDA for use in both the institutional and homecare settings. Breathe's pipeline includes a discreet for sleep apnea to improve user experience and address the unmet need in this market. Investors include Kleiner Perkins Caufield & Byers, Johnson & Johnson Development Corporation, Delphi Ventures, DAG Ventures, Morgan Creek, and Synergy Partners International. Breathe is located in Irvine, CA. For more information, please visit .
(1) Porszasz J, et al. Physiologic effects of an ambulatory ventilation system in COPD. Am J Respir Crit Care Med Vol 188, Iss. 3, pp 334-342, Aug 1, 2013
Image Available:
Stephanie Marks for Breathe Technologies
212-843-0211
Brian Baxter for Breathe Technologies
646-871-8491
Gary Berman
Vice President, Corporate Development & Finance
949-988 -7755
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.10.2013 - 13:00 Uhr
Sprache: Deutsch
News-ID 308514
Anzahl Zeichen: 0
contact information:
Town:
IRVINE, CA
Kategorie:
Medical Devices
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New Research Presented at CHEST 2013 Conference Highlights Breathe Technologies' Non-invasive Open Ventilation System"
steht unter der journalistisch-redaktionellen Verantwortung von
Breathe Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
